Výsledky vyhledávání - "Lindsay Hemmett"

Cost Effectiveness of Darunavir/Ritonavir 600/100mg bid in Treatment-Experienced, Lopinavir-Naive, Protease Inhibitor-Resistant, HIV-Infected Adults in Belgium, Italy, Sweden and the UK

Autor: Jonas Hjelmgren, Gabriele Allegri, K Moeremans, Lindsay Hemmett, Erik Smets

Publikováno v: PharmacoEconomics. 28:147-167

Background: Using data from the phase IIb POWER trials, darunavir boosted with low-dose ritonavir (DRV/r; 600/100 mg twice daily; bid)-based highly active antiretroviral therapy (HAART) was shown to be significantly more efficacious and cost effectiv

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ed95822aea74d657d697a9ffb9d216ab
https://doi.org/10.2165/11587500-000000000-00000

Zobrazit plný text záznamu

Predicting Direct Costs of HIV Care During the First Year of Darunavir-Based Highly Active Antiretroviral Therapy Using CD4 Cell Counts

Autor: Mickael Löthgren, Erik Smets, Lindsay Hemmett, Gabriele Allegri, Kelly A. Gebo, Andrew Hill

Publikováno v: PharmacoEconomics. 28:169-181

Given the association between CD4 cell counts and HIV-related morbidity/mortality, new antiretroviral therapies could potentially lower the direct costs of HIV care by raising CD4 cell counts.To predict the effects of the ritonavir-boosted, HIV prote

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::796bae02bf250e3a631e5ff30d6db032
https://doi.org/10.2165/11587510-000000000-00000

Zobrazit plný text záznamu

Analysis of Costs by CD4 Count Category for the Darunavir/r 600/100 mg bid and Control Protease Inhibitor Arms of the POWER 1 and 2 Trials

Autor: Lindsay Hemmett, Bernard Wilson, Andrew Hill

Publikováno v: HIV Clinical Trials. 8:303-310

HIV-infected people with low CD4 counts are at higher risk of AIDS and incur increased health care costs from in-patient stays and medications.In the POWER 1 and 2 trials, patients were treated with optimized nucleoside reverse transcriptase inhibito

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d8e8c64db386d415ef3c26dca7340f74
https://doi.org/10.1310/hct0805-303

Zobrazit plný text záznamu

A Cost-Effectiveness Analysis of Docetaxel in the Second-Line Treatment of Non-Small Cell Lung Cancer

Autor: David Dunlop, Lindsay Hemmett, Uday Bose, Jeremy Holmes, Peter Sharplin

Publikováno v: PharmacoEconomics. 22:581-589

Background: Whilst lung cancer is the most common form of cancer in England and Wales (annual incidence rate of 50 per 100 000) it does not always receive the policy attention accorded to other types of cancer, such as breast and colorectal. Neverthe

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6a17652a7f1ef76b536698b6c3df2c44
https://doi.org/10.2165/00019053-200422090-00003

Zobrazit plný text záznamu

The cost-effectiveness of human papillomavirus screening for cervical cancer. A review of recent modelling studies

Autor: Lindsay Hemmett, Jeremy Holmes, Susan Garfield

Publikováno v: The European journal of health economics : HEPAC : health economics in prevention and care. 6(1)

We compared findings from recent studies modelling the cost-effectiveness of screening for cervical cancer using human papillomavirus (HPV) testing and alternative strategies. Data were standardized to facilitate comparison of costs per life year or

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3246620add3a6286558e708ea5c2247b
https://pubmed.ncbi.nlm.nih.gov/15682286

Zobrazit plný text záznamu